Compression stockings in addition to low-molecular-weight heparin to prevent venous thromboembolism in surgical inpatients requiring pharmacoprophylaxis: the GAPS non-inferiority RCT

Joseph Shalhoub,¹ Rebecca Lawton,¹ Jemma Hudson,² Christopher Baker,³ Andrew Bradbury,⁴ Karen Dhillon,³ Tamara Everington,⁵ Manjit S Gohel,¹,⁶ Zaed Hamady,⁷ Beverly J Hunt,⁸ Gerard Stansby,⁹ David Warwick,¹⁰ John Norrie¹¹ and Alun H Davies¹*

on behalf of the GAPS trial investigators

¹Department of Surgery and Cancer, Imperial College London, London, UK
²Health Services Research Unit, University of Aberdeen, Aberdeen, UK
³Department of Surgery and Cancer, Imperial College Healthcare NHS Trust, London, UK
⁴College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK
⁵Department of Haematology, Hampshire Hospitals NHS Foundation Trust, Basingstoke, UK
⁶Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
⁷Southampton HPB Unit, University Hospital Southampton NHS Foundation Trust, Southampton, UK
⁸Department of Thrombosis and Haemostasis, Guy’s & St Thomas’ NHS Foundation Trust, London, UK
⁹Northern Vascular Unit, Freeman Hospital, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK
¹⁰Department of Trauma and Orthopaedic Surgery, University Hospital Southampton NHS Foundation Trust, Southampton, UK
¹¹Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK

*Corresponding author a.h.davies@imperial.ac.uk

Declared competing interests of authors: Alun H Davies reports other grants from the National Institute for Health Research (NIHR), the Stroke Association (London, UK), the Graham–Dixon Charitable Trust, Sir Halley Stewart Trust, the J P Moulton Charitable Foundation, Laboratoires URGO SA (Chenôve, France) and Actegy Health Ltd (Bracknell, UK) during the conduct of the study, none of which is related to the submitted work. Manjit S Gohel reports personal fees and Advisory Board speaker fees from Medtronic plc (Dublin, Ireland) and from Cook Medical (Bloomington, IN, USA), and grants from Laboratoires URGO SA outside the submitted work. John Norrie reports
membership of the following NIHR boards: Commissioning Priority Review Decision-making Committee (2015); Health Technology Assessment (HTA) Commissioning Board (2010–16); HTA Commissioning Sub-board (expression of interest) (2014); HTA Funding Boards Policy Group (2016–19); HTA General Board (2016–19); HTA post-board funding teleconference (2016–19); NIHR Clinical Trials Unit Standing Advisory Committee (2018 to present); NIHR HTA and Efficacy and Mechanism Evaluation Editorial Board (2014–19); and the Pre-exposure Prophylaxis Impact Review Panel (2017). Andrew Bradbury and Joseph Shalhoub report grants from NIHR during the conduct of the study.
Scientific summary

Background

Venous thromboembolism encompassing deep-vein thrombosis and pulmonary embolism is a leading cause of preventable death in patients admitted to hospital. In addition, just under half of patients with deep-vein thrombosis will go on to develop a post-thrombotic limb, representing significant health burden and societal costs. Surgical patients are at an increased risk of venous thromboembolism, but effective venous thromboembolism prophylaxis can reduce the risk in this group by half.

In 2005, the Department of Health and Social Care commissioned the National Institute for Health and Care Excellence to produce guidance on measures to prevent venous thromboembolism for surgical patients. The guideline recommended that surgical patients assessed as being at a moderate or high risk of venous thromboembolism, in whom there are no contraindications and who are at a low risk of major bleeding, should receive both pharmacological thromboprophylaxis, such as low-molecular-weight heparin, and mechanical thromboprophylaxis in the form of graduated compression stockings.

The benefit of graduated compression stockings has recently been called into question, and a systematic review found limited evidence to support the use of graduated compression stockings in addition to pharmaco-thromboprophylaxis in surgical inpatients. Patients’ ‘real world’ experience of stockings is poor and is associated with a number of undesired effects, including discomfort, ischaemia and blistering. The risk of venous thromboembolism needs to be balanced against the risk of preventative measures, both mechanical and pharmacological.

Objectives (list of research questions)

1. Primary objective: to determine whether or not low-dose low-molecular-weight heparin alone is non-inferior to a combination of low-dose low-molecular-weight heparin plus graduated compression stockings for the prevention of venous thromboembolism in adult elective surgical inpatients.

2. Secondary objectives:
   i. to profile the adverse effects of graduated compression stockings and low-molecular-weight heparin
   ii. to determine compliance with low-molecular-weight heparin and/or graduated compression stockings during admission
   iii. to compare quality of life between those receiving low-molecular-weight heparin alone and those receiving both low-molecular-weight heparin and graduated compression stockings
   iv. to provide evidence to support future guidance and policy in venous thromboembolism prevention.

Methods

Design

A multicentre, prospective, non-inferiority randomised controlled trial to compare venous thromboembolism outcomes in surgical inpatients assessed as being at a moderate or high risk of venous thromboembolism who are prescribed graduated compression stockings in addition to low-dose low-molecular-weight heparin with those prescribed low-dose low-molecular-weight heparin alone.
Setting
Seven secondary care NHS hospitals across England performing a variety of surgical procedures.

Participants
Between May 2016 and 31 January 2019, 1905 participants were randomised into the graduated compression as an adjunct to thromboprophylaxis in surgery (GAPS) trial. Follow-up was completed on 1 May 2019. Written informed consent was obtained from all participants, who then underwent eligibility assessments. Participants who met the inclusion and exclusion criteria were randomised 1 : 1 to either low-molecular-weight heparin alone (intervention) or low-molecular-weight heparin plus graduated compression stockings (standard care).

Inclusion criteria
- Elective surgical inpatients assessed as being at a moderate or high risk of venous thromboembolism according to the widely-used UK NHS England venous thromboembolism risk assessment tool for venous thromboembolism (or the trust equivalent based on this form) (based on the National Institute for Health and Care Excellence recommendations).
- Able to give informed consent to participate in the trial after reading the patient information documentation.
- Aged ≥ 18 years.

Exclusion criteria
- Contraindications to low-molecular-weight heparin.
- Contraindications to graduated compression stockings, including peripheral arterial disease, stroke patients and individuals undergoing lower limb surgery.
- Documented or known thrombophilia or thrombogenic disorder.
- Individuals requiring therapeutic anticoagulation.
- Previous venous thromboembolism.
- Patients having intermittent pneumatic compression beyond theatre and recovery.
- Patients requiring inferior vena cava filter.
- Pregnancy (female participants of reproductive age were eligible for inclusion in the trial, subject to a negative pregnancy test prior to randomisation and again on the day of surgery if there was a possibility of pregnancy since the last test).
- Patients requiring thromboprophylaxis to be extended beyond discharge.
- Application of a cast or brace in theatre.

Randomisation
Randomisation (1 : 1) was web based and hosted by the Centre for Healthcare Randomised Trials. A minimisation algorithm incorporating centre, moderate or high risk of venous thromboembolism and sex was used in addition to an incorporated random element.

Interventions
Graduated compression stockings, sometimes known as medical compression stockings or anti-embolism stockings, work by exerting pressure at the ankle that gradually decreases up the garment to the knee or thigh. The pressure gradient ensures that blood flows towards the heart, minimising reflux to the foot or laterally into the superficial veins.

Low-molecular-weight heparins at a thromboprophylactic dose are a safe and effective agent for the prevention of venous thromboembolism, particularly as they do not require regular monitoring or require dose adjustments. This has led to their increased use as thromboprophylaxis in both medical and surgical patients.
Outcomes and follow-up

The primary outcome was symptomatic or asymptomatic venous thromboembolism up to 90 days after surgery, which was confirmed by imaging (duplex ultrasound scan performed between days 14 and 21 after surgery or, if clinical suspicion, at any time up to 90 days after surgery). Secondary outcomes included quality of life over 90 days, as measured by a generic health-related quality-of-life tool, EuroQol-5 Dimensions, five-level version; compliance with low-molecular-weight heparin and graduated compression stockings, as measured against hospital drug charts and self-report participant diaries; and overall mortality.

Participants in both treatment arms were followed up at 7 days post surgery or at discharge (whichever was earlier). Low-molecular-weight heparin compliance, graduated compression stockings compliance (in the graduated compression stockings arm alone) and imaging-confirmed venous thromboembolism were recorded by the research nurse. All patients were invited to return to hospital between 14 and 21 days after surgery to undergo a full bilateral duplex ultrasound scan of their legs carried out by a vascular scientist. The final follow-up was conducted 90 days after surgery to record health resource use and imaging-confirmed venous thromboembolism. The EuroQol-5 Dimensions, five-level version, was administered at baseline and at each follow-up either in person or via the telephone, or the patient could self-complete electronically via the database.

Results (research findings)

A total of 1905 participants were randomised, of whom 1858 were included in the intention-to-treat analysis. A primary outcome event occurred in 16 out of 937 (1.7%) patients in the low-molecular-weight heparin-alone arm compared with 13 out of 921 (1.4%) in the low-molecular-weight heparin plus graduated compression stockings arm. The risk difference between low-molecular-weight heparin alone and low-molecular-weight heparin plus graduated compression stockings was 0.30% (95% confidence interval -0.65% to 1.26%). As the 95% confidence interval did not cross the non-inferiority margin of 3.5% ($p < 0.001$), the non-inferiority of low-molecular-weight heparin alone was shown.

Conclusions

The results of the GAPS trial indicate that among elective surgical patients assessed as being at a moderate or high risk of venous thromboembolism, administration of pharmacological thromboprophylaxis alone is non-inferior to a combination of pharmacological thromboprophylaxis plus graduated compression stockings.

Implications for health care

Findings from this trial suggest that in elective surgical patients requiring pharmacological thromboprophylaxis, adjuvant graduated compression stockings are unlikely to be of benefit.

Recommendations for research (numbered in priority order)

1. Examination of stakeholders’ views of the findings of the GAPS trial and its impact on future clinical practice.
2. Randomised trial of inpatient graduated compression stockings use versus no inpatient graduated compression stockings use in patients requiring extended pharmacological thromboprophylaxis (while inpatient and beyond hospital discharge) following surgery.
3. Randomised trial to evaluate whether or not adjuvant graduated compression stockings have a role in patients undergoing emergency surgical procedures.
4. Randomised trial of patients assessed as being at a low risk of venous thromboembolism: inpatient graduated compression stockings use versus no inpatient graduated compression stocking use.
**Trial registration**

This trial is registered as ISRCTN13911492.

**Funding**

This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in *Health Technology Assessment*; Vol. 24, No. 69. See the NIHR Journals Library website for further project information.
Criteria for inclusion in the Health Technology Assessment journal

Reports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

Reviews in Health Technology Assessment are termed ‘systematic’ when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

HTA programme

Health Technology Assessment (HTA) research is undertaken where some evidence already exists to show that a technology can be effective and this needs to be compared to the current standard intervention to see which works best. Research can evaluate any intervention used in the treatment, prevention or diagnosis of disease, provided the study outcomes lead to findings that have the potential to be of direct benefit to NHS patients. Technologies in this context mean any method used to promote health; prevent and treat disease; and improve rehabilitation or long-term care. They are not confined to new drugs and include any intervention used in the treatment, prevention or diagnosis of disease.

The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.

This report

The research reported in this issue of the journal was funded by the HTA programme as project number 14/140/61. The contractual start date was in December 2015. The draft report began editorial review in December 2019 and was accepted for publication in July 2020. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. This report has been published following a shortened production process and, therefore, did not undergo the usual number of proof stages and opportunities for correction. The HTA editors and publisher have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health and Social Care. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health and Social Care.

© Queen’s Printer and Controller of HMSO 2020. This work was produced by Shalhoub et al. under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).
Editor-in-Chief of *Health Technology Assessment* and NIHR Journals Library

**Professor Ken Stein**  Professor of Public Health, University of Exeter Medical School, UK

---

NIHR Journals Library Editors

**Professor John Powell**  Chair of HTA and EME Editorial Board and Editor-in-Chief of HTA and EME journals. Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK, and Professor of Digital Health Care, Nuffield Department of Primary Care Health Sciences, University of Oxford, UK

**Professor Andréé Le May**  Chair of NIHR Journals Library Editorial Group (HS&DR, PGfAR, PHR journals) and Editor-in-Chief of HS&DR, PGfAR, PHR journals

**Professor Matthias Beck**  Professor of Management, Cork University Business School, Department of Management and Marketing, University College Cork, Ireland

**Dr Tessa Crilly**  Director, Crystal Blue Consulting Ltd, UK

**Dr Eugenia Cronin**  Senior Scientific Advisor, Wessex Institute, UK

**Dr Peter Davidson**  Consultant Advisor, Wessex Institute, University of Southampton, UK

**Ms Tara Lamont**  Senior Scientific Adviser (Evidence Use), Wessex Institute, University of Southampton, UK

**Dr Catriona McDaid**  Senior Research Fellow, York Trials Unit, Department of Health Sciences, University of York, UK

**Professor William McGuire**  Professor of Child Health, Hull York Medical School, University of York, UK

**Professor Geoffrey Meads**  Emeritus Professor of Wellbeing Research, University of Winchester, UK

**Professor John Norrie**  Chair in Medical Statistics, University of Edinburgh, UK

**Professor James Raftery**  Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

**Dr Rob Riemsma**  Reviews Manager, Kleijnse Systematic Reviews Ltd, UK

**Professor Helen Roberts**  Professor of Child Health Research, UCL Great Ormond Street Institute of Child Health, UK

**Professor Jonathan Ross**  Professor of Sexual Health and HIV, University Hospital Birmingham, UK

**Professor Helen Snooks**  Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

**Professor Ken Stein**  Professor of Public Health, University of Exeter Medical School, UK

**Professor Jim Thornton**  Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Nottingham, UK

**Professor Martin Underwood**  Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, UK

Please visit the website for a list of editors: [www.journalslibrary.nihr.ac.uk/about/editors](http://www.journalslibrary.nihr.ac.uk/about/editors)

**Editorial contact:** journals.library@nihr.ac.uk